Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02499575 · ClinicalTrials.gov registry record · NA
Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures
A NA study, sponsored by OhioHealth.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02499575 is a NA study that was terminated before completion, run by OhioHealth. The registered enrollment target is 2 participants.
The verdict
NCT02499575, a NA study, was terminated before completion, sponsored by OhioHealth.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
Exparel is an FDA-approved local anesthetic (bupivacaine), in a long-release formulation. In this study the investigators plan to determine the ability of Exparel to control post-operative pain in common first metatarsophalangeal (MTP) joint procedures (bunion surgery, 1st MTP fusion, and cheilectomy).
Interventions
- DRUG Exparel
- DRUG 0.5% ropivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02499575
The ClinicalTrials.gov registry entry for NCT02499575 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OhioHealth, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exparel is the first listed.
NCT02499575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02499575 about?
NCT02499575 is a clinical study titled "Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures". Exparel is an FDA-approved local anesthetic (bupivacaine), in a long-release formulation. In this study the investigators plan to determine the ability of Exparel to control post-operative pain in common first metatarsophalangeal (MTP) joint procedures (bunion surgery, 1st MTP fusion, and cheilectom...
What is the current status of trial NCT02499575?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2015-07. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02499575?
The interventions under investigation include: Exparel (DRUG), 0.5% ropivacaine (DRUG).
Who is sponsoring clinical trial NCT02499575?
This trial is sponsored by OhioHealth, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.